Comparison of S‐1 plus oxaliplatin (SOX) and capecitabine plus oxaliplatin (XELOX) as adjuvant chemotherapies for stage II and III gastric cancer after D2 resection: A single‐center retrospective study

BACKGROUND: Capecitabine plus oxaliplatin (XELOX) as adjuvant therapy for gastric cancer (GC) reduces cancer recurrence and improves survival. S‐1 plus oxaliplatin (SOX) is well‐tolerated and effective against advanced GC, and also be used widely in adjuvant treatment. However, data comparing SOX an...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Asia Pac J Clin Oncol
Main Authors: Jiang, Zhichao, Sun, Yongkun, Zhang, Wen, Cui, Chengxu, Yang, Lin, Zhou, Aiping
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2020
Teme:
Original Articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7318315/
https://ncbi.nlm.nih.gov/pubmed/32077628
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ajco.13321
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki